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DSUMMARY
Binding of polo-like kinase 1 (Plk1) polo-box domains
(PBDs) to phosphothreonine (pThr)/phosphoserine
(pSer)-containing sequences is critical for the proper
function of Plk1. Although high-affinity synthetic
pThr-containing peptides may be used to disrupt
PBD function, the efficacy of such peptides in whole
cell assays has been poor. This potentially reflects
limited cell membrane permeability arising in part
from the di-anionic nature of the phosphoryl group.
We report five-mer peptides containing mono-
anionic pThr phosphoryl esters that exhibit single-
digit nanomolar PBDbinding affinities in extracellular
assays and improved antimitotic efficacies in whole
cell assays. The cellular efficacies of these peptides
have been further enhanced by the application of
bio-reversible pivaloyloxymethyl (POM) phosphoryl
protection to a pThr-containing polypeptide. Our
findings may redefine structural parameters for the
development of PBD-binding peptides and peptide
mimetics.
INTRODUCTION
Phosphoamino acid-dependent protein-protein interactions
(PPIs) involving phosphotyrosine (pTyr) or phosphothreonine
(pThr)/phosphoserine (pSer) residues serve central roles in a
variety of normal and disease processes (Elia and Yaffe, 2005;
Ladbury, 2005; Yaffe, 2002). The particular reliance of these in-
teractions on phosphoryl moieties for affinity and on the amino
acid sequences proximal to the phosphoamino acid residue for
selectivity renders such PPIs ‘‘hot spot’’ in nature, and thereby
potentially amenable to disruption by small-to-moderate size
molecules (Clackson and Wells, 1995; Geppert et al., 2011;
Moreira et al., 2007; Ofran and Rost, 2007). Development of
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tional area. Typically, short phosphopeptides modeled on
cognate recognition sequences provide starting points for trans-
formation into more drug-like peptide mimetics. However, phos-
phopeptides present particular challenges to cellular studies,
due to the poor membrane transport of phosphoryl di-anionic
species (Allentoff et al., 1999; Richter et al., 2009). Overcoming
the paradoxical importance of the phosphoryl pharmacophore
in promoting high binding affinity while at the same time serving
as a limiting factor in cell membrane transport is among the
primary obstacles faced in the development of phospho-depen-
dent PPI inhibitors (Burke and Lee, 2003). Traditionally, mini-
mizing charge has been achieved either with less charged
phosphoryl mimetics or by masking the acidic phosphoryl
hydroxyls with bioreversible prodrug moieties.
The polo-like family of serine/threonine protein kinases (Plk1-
Plk5; collectively called Plks) play pivotal roles in cell cycle regu-
lation and cell proliferation (Archambault and Glover, 2009; Barr
et al., 2004; Dai, 2005; Lowery et al., 2005; van de Weerdt and
Medema, 2006). Plks contain N-terminal catalytic domains as
well as C-terminal polo-box domains (PBDs) that bind to ‘‘Ser-
pSer/pThr’’-containing motifs. These latter phospho-dependent
PPIs provide sub-cellular localization required for proper Plk
function (Cheng et al., 2003; Elia et al., 2003a, 2003b; Park
et al., 2010). Plk1 has been recognized among Plk family mem-
bers as a potential anticancer therapeutic target and significant
effort has been directed at developing Plk1 kinase domain inhib-
itors (Goh et al., 2004; Gumireddy et al., 2005; Lansing et al.,
2007; Le´na´rt et al., 2007; Lu and Yu, 2009; McInnes et al.,
2005; McInnes and Wyatt, 2011; Reindl et al., 2009; Strebhardt,
2010; Weiß and Efferth, 2012). However, a potential drawback
of kinase domain inhibitors is low specificity resulting from
similarities among the ATP-binding clefts of Plks. A lack of spec-
ificity would be undesirable because downregulation of Plk1
with concomitant inhibition of the closely related Plk2 or Plk3
would be contraindicated due to the positive roles these latter
kinases play in maintaining genetic stability (Burns et al., 2003;
Xie et al., 2005). The uniqueness of PBDs makes disruption of
PBD-dependent PPIs an attractive alternative to kinase domain
C264, October 24, 2013 ª2013 Elsevier Ltd All rights reserved 1255
Figure 1. Structures of Mono-Anionic Esters 2b–2n
See also Figure S1.
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Peptidic pThr Esters Targeting Plk1 PBDinhibitors as a means of selectively downregulating the function
of Plks (Jang et al., 2002; Lee et al., 1998; Reindl et al., 2008;
Seong et al., 2002; Strebhardt and Ullrich, 2006; Watanabe
et al., 2009; Yun et al., 2009).
In our efforts to develop highly potent Plk1 PBD-binding inhib-
itors, we recently reported that introduction of long-chain alkyl
phenyl groups onto the d1 nitrogen (N3) of the His imidazole
ring of the PBIP1-derived peptide ‘‘PLHSpT’’ (1) to form peptides
such as 2a can impart up to 1,000-fold PBD-binding affinity
enhancement through interaction of the His-adduct moiety
within a cryptic hydrophobic binding pocket on the surface of
the PBD (Protein Data Bank accession code: 3RQ7; Figure 1;
Liu et al., 2011). Our subsequent work (Liu et al., 2012a,
2012b; Qian et al., 2012) as well as the work of others (Sledz
et al., 2011, 2012), has demonstrated that aryl functionality teth-
ered from a variety of locations along the peptide chain can bind
in the newly discovered hydrophobic channel. Among the pep-
tides reported to date, the alkyl-His residue in peptide 2a may
be viewed as ‘‘privileged’’ in its ability to access this new binding
region because of its proximity to key signature residues, ‘‘Ser-
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makes peptides such as 2a ideal starting points for inhibitor
design. However, despite low nanomolar PBD-binding affinity
in in vitro assays, peptides related to 2a achieve effects in cell
culture assays only at very high concentrations (Liu et al.,
2011). This low cellular efficacy could potentially have resulted
from poor cell membrane permeability, which may be attribut-
able in part to the phosphoryl di-anionic charge. As with other
phospho-dependent PPIs, overcoming limitations imposed by
poor cell membrane permeability of phosphoryl functionality is
a general challenge in the field of PBD-binding inhibitor develop-
ment. Our current paper details our efforts at addressing issues
related to the phosphoryl group of peptide 2a that combine con-
version of acidic phosphoryl hydroxyls to mono-anionic ester
species together with further transformation to noncharged spe-
cies through bioreversible prodrug protection.
RESULTS
Conceptual Approach
The importance for PBD ligand binding of the interactions
between the ligand pThr phosphoryl group and the positively
charged PBD residues H538 and K540 has been shown both
by X-ray crystal data and by mutational studies (Elia et al.,
2003a). The apparent key role of a di-anionic phosphoryl group
is supported by our recent studies, where conversion of the
pThr group in peptide 1 to mono-anionic esters resulted in sub-
stantial or complete abolition of binding affinity (Liu et al., 2011).
However, we hypothesized that peptides such as 2a that contain
an alkyl-His residue may allow the replacement of pThr residues
with mimetics having reduced anionic charge while retaining
high binding affinity. Using the His-adduct-containing peptide
2a as a platform, we recently examined pThr mimetics having
mono-anionic phosphinic acid, sulfonic acid, and carboxylic
acid functionality as well as di-anionic pSer, a b,b-bis-methyl
variant of pSer and p(allo-Thr) (Qian et al., 2013). We found
that only the di-anionic phosphonic acid and phosphate-con-
taining analogs retained high binding-affinity.
Synthesis and Evaluation of Alkyl-His-Containing
Peptides Having Mono-anionic pThr Esters
In our current work, we revisited the issue of mono-anionic pThr
esters within the context of platform 2a. We prepared a series of
mono-anionic phosphoryl esters (2b–2n; Figure 1) by solid-
phase techniques using our recently reported chemistry for
introducing alkyl-His residues (Qian et al., 2011) together with
Mitsunobu phosphoryl esterification as a final step prior to resin
cleavage (Figure S1 available online; Liu et al., 2011). When we
examined the resulting peptides in ELISA-based Plk1 PBD inhi-
bition assays, we found that, in contrast to the loss of potent
binding affinity observed with mono-anionic esters of 1 (Liu
et al., 2011), members of the currents series retained good
PBD-binding affinity, which in some cases equaled or exceeded
that of the parent di-anionic peptide 2a (Table 1 and Figure S2).
An example of the dramatic enhancement in inhibitory activity of
mono-esters incurred by the inclusion of the alkyl-His moiety is
provided by 2l, where greater than a five-orders of magnitude
difference was observed as compared to the same peptide lack-
ing the alkyl-His moiety (half-maximal inhibitory concentration
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Table 1. Plk1 PBD Affinities
Entry Compound IC50 (mM)
1 PLHST NA
2 1 9
3 2a 0.003
4 2ay 0.003
5 2b 0.005
6 2c 0.001
7 2c (S/A) 0.8
8 2d 0.001
9 2e 0.001
10 2f 0.004
11 2g 0.005
12 2h 0.006
13 2i 0.04
14 2j 0.003
15 2k 0.002
16 2l 0.001
17 2 m 0.001
18 2 m(S/A) 0.15
19 2n 0.015
Determined by ELISA competition assays as described. Binding curves
are shown in Figure S2.
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Peptidic pThr Esters Targeting Plk1 PBD[IC50] = 0.001 mM for 2l versus IC50 > 200 uMwithout the alkyl-His
moiety; Liu et al., 2011). We also examined the effects of deriva-
tization of both acidic phosphoryl oxygens in 2a to yield the
uncharged bis-methyl and bis-(2-hydroxyethyl) esters. While
being much less potent than the corresponding mono-anionic
esters in ELISA-based binding assays, the ability of these ana-
logs to retain sub-micromolar affinities indicated that phosphoryl
anionic charge is not absolutely required for binding within the
context of the alkyl-His-containing platform 2a. However, the un-
charged di-ester peptides exhibited marginal effects in cellular
assays and they were not pursued further (data not shown).
Given the similarities in inhibitory potencies among the series,
we considered peptides showing marginally better IC50 values
as potential candidates for cell-based studies (2c, 2d, 2e, 2l
and 2 m; IC50 = 0.001 mM, Table 1). Of these, 2e was omitted
due to the presence of an anionic carboxylic acid group. Prelim-
inary cellular evaluation of the remaining members of the series
showed that the hydroxyl-containing analogs (2c, 2l and 2m) ex-
hibited significantly higher potencies than the non-hydroxyl-con-
taining analog (2d). This may potentially indicate a beneficial role
for hydroxyl functionality in these assays. Interestingly, 2l and
2 m showed identical potencies in spite of the diastereomeric
hydroxyls in their ester functionalities. Based on the above we
selected peptides 2c and 2 m for more in-depth evaluation.
To rule out promiscuous modes of binding (Coan et al., 2009;
McGovern, 2006), the Ser to Ala mutants (S4A) of 2c and 2 m
were prepared, since the Ser residue provides key recognition
features for canonical Plk1 PBD binding and replacement with
an Ala residue is known to significantly reduce binding affinity
(Elia et al., 2003a). Consistent with nonpromiscuous binding,
our current study showed that the Ser to Ala substituted peptides
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inhibitory potencies [2c(S4A) IC50 = 0.8 mM and 2 m(S4A)
IC50 = 0.15 mM] (Table 1 and Figure S2).
X-Ray Crystal Structure
To unambiguously establish its mode of binding, the X-ray co-
crystal structure of 2m complexedwith the Plk1 PBDwas solved
(Figure 2 and Figure S3). The Plk1 PBD interactions of di-anionic
phosphopeptides PLHSpT (Protein Data Bank code: 3HIK; Yun
et al., 2009) and 2a (Protein Data Bank code: 3RQ7; Liu et al.,
2011) have been previously reported. In our current work, we
observed that both the protein backbone and the peptide ligand
in the PBD,2 m complex were essentially superimposable with
the PBD,2a structure (Figure 2A).Within the vicinity of the ligand,
only the side chains of F559 and Q536 showed significant varia-
tion with the 2a structure, and the effects of these differences on
ligand binding were not obvious. Of particular note was the close
correspondence of the key phosphoryl-interacting residues
H538 and K540 as well as of the phosphoryl groups themselves
(Figure 2B). We have interpreted the electron density for the (3R)-
3,4-dihydroxybutyl ester group, which is poorly defined, as
corresponding to two alternate conformations, each of which
originates from the same phosphoryl oxygen. This oxygen is at
a hydrogen bonding distance of 2.5 A˚ from the key K540 side
chain amine. The two remaining free phosphoryl oxygen atoms
were observed to hydrogen bond with the H538 imidazole nitro-
gen (2.8 A˚) and the amide proton of the Ser-pThr bond, respec-
tively (Figure 2B). It should be noted that K540 interacts with 2a
via a salt bridge, while with 2 m this is a hydrogen bonding inter-
action. One potential reason why the replacement of this salt
bridge with a hydrogen bond does not result in reduced binding
affinity for 2 m may derive from differences in the number and
arrangement of bound waters within the phosphoryl-binding
pocket occupied by 2 m relative to what is observed for the
parent 2a. In particular, a total of six bound waters originally pre-
sent in the 2a structure (PBD 3RQ7 designations: wa40, wa105,
wb, wb4, wb16 and wb15) are absent from the structure of 2 m
(Figure 2C). Release of constrained waters into the solvent can
contribute in a positive fashion to binding affinity (Huggins
et al., 2010) and the displacement of bound waters may be
one reason for the general retention of binding affinity for the
series of mono-anionic esters 2b–2n.
Plk-Binding Specificity by Fluorescence Polarization
In order to evaluate Plk1 specificity, we introduced fluorescein
isothiocyanate (FITC) groups into 2a, 2c, and 2 m via N-terminal
PEG tethers (designated as 2a*, 2c*, and 2 m*; Figure S4) and
determined binding constants to PBDs fromPlk1, 2 and 3 (desig-
nated as PBD1, PBD2 and PBD3, respectively) using fluores-
cence polarization techniques (Figure S4). We had previously
shown for 2a that such modification had little effect on binding
affinity (Liu et al., 2011). In the current work, we found that 2a*,
2c* and 2 m* bound to PBD1 with dissociation constants (KD
values) of 12 nM, 2 nM, and 3 nM, respectively (Table 2). Selec-
tivities of 2a*, 2c*, and 2 m* for PBD1 relative to PBD2 were
33-fold (400 nM), 21-fold (43 nM), and 8-fold (24 nM), respec-
tively, while the corresponding selectivities for PBD1 relative to
PBD3 were 25-fold (306 nM), 120-fold (240 nM), and 20-fold
(62 nM), respectively.
C
TE
D264, October 24, 2013 ª2013 Elsevier Ltd All rights reserved 1257
Figure 2. X-Ray Crystal Structure of the
Mono-Anionic Phosphothreonine Ester-
Containing 2 m Bound to Plk1 PBD
Compared with the Structure of the PBD,2a
Complex
(A) Superposition of the two structures with protein
backbones rendered as ribbons (2a complex,
blue; 2 m complex, gray). The ligands are color-
coded (2a, purple; 2 m carbons, yellow) and the
side chains of Q536, H538, K540, and F559 are
shown (2m complex, carbons, white; 2a complex,
carbons, purple).
(B) Enlargement of the pThr-binding pocket
showing key hydrogen-bonding interactions of
the phosphoryl oxygens of 2 m as well as two
orientations of its ester group. Color coding is as
described for (A).
(C) The pThr binding pocket of the PBD,2 m
complex showing 2mwith proximal bound waters
(red spheres) along with bound waters observed
in the PBD,2a complex (cyan spheres). Waters
present in the 2a complex but not in the 2 m
complex are indicated with water numbering as
given in Protein Data Bank code 3RQ7.
See also Figure S3.C
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Peptidic pThr Esters Targeting Plk1 PBDIn the absence of crystal structures for PBD2 and PBD3, the
bases for selective binding to PBD1 relative to PBD2 and
PBD3 are not obvious. However, alignment of the sequences
for the three PBDs (Elia et al., 2003a; Park et al., 2010) provides
insights into potential reasons for ligand selectivity. These
include interactions of the N-terminal Pro-Leu residues with a
region defined by Arg516 and Phe535 in PBD1 but which corre-
sponds to Lys and Tyr residues, respectively, in PBD2 and
PBD3. In addition, the Leu490 residue in PBD1 corresponds to
a Met residue in PBD2 and PBD3. This lies in a region of the
PBD proximal to the ligand pThr-2 His residue, which had been
shown to contribute to PBD1 selectivity enhancement (Yun
et al., 2009). It is noteworthy that despite the important contribu-
tion to overall ligand affinity made by the interaction of alkyl-His
adduct moiety within a hydrophobic channel, that the residues
lining this channel are highly conserved among the three
PBDs. Variations occur only at the PBD1 Leu478 position, which
corresponds to a Val in PBD2 and an Ile in PBD3, and at the
PBD1 Y421 position, which is conserved in PBD2, but which is
a Phe residue in PBD3. Residues lining the pThr-binding pocket
are highly conserved among the three PBDs.
Cell-Based Assays
Next, we examined the effect of peptides in cultured HeLa cells.
In these experiments, we used 2ay (Figure 1) as a reference. This
previously reported variant (Liu et al., 2011) of 2a, in which the
pThr residue is replaced by a (2S,3R)-2-amino-3-methyl-4-phos-
phonobutyric amide residue (Liu et al., 2009) and an N-terminal
PEG group has been appended to increase water solubility, rep-
resents the most potent peptide we have yet reported in cell-
based assays (Liu et al., 2011). In our current work, 2ay was
able to induce partial mitotic block in asynchronously growing
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of mitotically arrested cells at 24 hr after treatment being more
than doubled the percentage at 12 hr after treatment. A maximal
mitotic index of approximately 35% was observed after expo-
sure for 24 hr at the highest concentration used (600 mM; Fig-
ure 3). Under these conditions, treatment with 2c achieved
significant levels of mitotic block, with 200 mM and 600 mM con-
centrations resulting inmitotic indices of approximately 40%and
65%, respectively after 24 hr. Treatment with 2 m resulted in
similar, although slightly reduced effects. In both cases, the cor-
responding S/A mutants, 2c(S4A) and 2 m(S4A), respectively,
gave significantly attenuated effects, supporting a Plk PBD-
dependent mechanism of action (Figure 3).
We have previously shown that treatment of cells with 2ay
decreases cell proliferation rate due to PBD inhibition-induced
apoptotic cell death (Liu et al., 2011). In a similar fashion, the
mitotic block observed in our current work is reflected in even
stronger antiproliferative effects, which were measured by plot-
ting relative cell numbers for each dose at 12, 24 and 48 hr
(Figure 4). An IC50 value of 320 mM for 2a
y is consistent with
the previously reported IC50 value of 380 mM (Liu et al., 2011).
Approximate IC50 values of 85 mM and 90 mM obtained for 2c
and 2 m, respectively, represent marked improvements relative
to 2ay, while the corresponding S/A mutants, 2c(S4A) and
2 m(S4A), showed significantly reduced effects.
Prodrug Derivatization of 2c
In ELISA PBD inhibition assays of the current study, 2a, 2ay, 2c,
and 2m all displayed similar IC50 values (Table 1). The lower IC50
value of 2ay relative to our previously reported value for this pep-
tide (3 nM versus 30 nM; Liu et al., 2011) stems from variability in
the ELISA assay (the ELISA optical density at 450 nm [OD450]lsevier Ltd All rights reserved
Figure 3. Percent of Cultured HeLa Cells in Mitosis
(A and B) Percent after treatment with the indicated concentrations of peptides
for 12 hr (A) and 24 hr (B) is shown.
Table 2. Determination of PBD Selectivity
Entry Compoundb
KD (nM)
a
PBD1 PBD2c PBD3c
1 2a* 12 400 [333] 306 [253]
2 2c* 2 43 [21] 240 [120]
3 2 m* 3 24 [8] 62 [20]
aDetermined by fluorscence polarization assays using FITC-labeled
ligands.
bDesignation with an ‘‘*’’ indicates the presence of an N-terminal PEG-
FITC group as described in Figure S4.
cValues in brackets refer to the fold-change in binding affinity relative to
PBD1. Binding curves are shown in Figure S4.
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Peptidic pThr Esters Targeting Plk1 PBDvalues vary depending on the length of developing time). The
enhanced cellular activities shown by 2c and 2 m relative to
2ay could be attributable to a number of factors. While 2c and
2 m utilize phosphoryl esters and contain N-terminal acetyl
groups, 2ay uses the phosphonic acid-based pThr mimetic,
Pmab, and has an N-terminal PEG group. A component of the
improved cellular efficacy of 2c and 2 m may arise from
improved cell membrane transit, potentially achieved through
neutralization of one phosphoryl anionic charge. A logical exten-
sion is that neutralization of the remaining anionic charge could
further enhance cellular activity. A general strategy for increasing
the bioavailability of phosphates is to mask their acidic function-
ality with ‘‘prodrug’’ groups that can be removed enzymatically
once the agent is within the cell (Hecker and Erion, 2008; Schultz,
2003). The pivaloyloxymethyl (POM) moiety is a form of phos-
phoryl prodrug protection that has been widely used in nucleo-
tides (Hecker and Erion, 2008). One potential limitation of
bis-POM phosphoryl protection is that while cleavage of a first
POM group by esterases may be facile, subsequent cleavage
of a second POM group in the presence of a newly generated
anionic hydroxyl can often be problematic (Srivastva and Farqu-
har, 1984). However, application of this prodrug strategy to the
mono-anionoic ester 2c to yield the corresponding mono-
POM-containing product would not suffer from this limitation,
since cleavage of only a single POM group would be required
to yield the active mono-anionic form. With this in mind, we pre-
pared 3 as a neutral variant of 2c bearing a single POM group
(Figure S5).
Stability of Prodrug Protected Peptide 3 toward
Enzymatic Deprotection
A successful prodrug strategy requires that the chosen deriva-
tive exhibit sufficient stability to allow delivery to the desired
site of action, yet once there, that biocleavage occurs within a
biologically relevant time frame. Stability of esterase-labile pro-
drugs is often approximated using in vitro assays that use readily
available pig liver esterase (PLE). Because it was also important
to examine the stability of the POM group within the more rele-
vant contexts of cell culture media and intracellular milieu, we
performed these experiments as well. We found that conversion
of 3 to 2c occurred with a half-life of approximately 240 min in
control PLE (Figure S6A). In culture media, the half-life of 3 at a
concentration of 1 mM was approximately 400 min (Figure S6B).
In addition, at a more relevant concentration of 200 mM, conver-
sion of 3 to 2c in culture media did not occur to any appreciable
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lysates showed that 50% conversion to 2c occurred in approxi-
mately 90 min (Figure S6C).
These data indicate that in cell culture studies, 3 should persist
in relatively unchanged form in the extracellular media, yet be
rapidly converted to the active form 2c once inside the cell. Inter-
estingly, because the in vitro ELISA-based PBD-inhibition assay
utilizes cell lysates, significant conversion of 3 to 2c could occur
during the course of a typical assay. Indeed, the inhibitory
potency of 3 was found to increase from 0.02 mM to 0.002 mM
by a 1.5 hr pre-incubation prior to conducting the standard assay
(Table 3 and Figure S5).
Cell-based Assays Using POM-Protected 3
The effect of POM-protection in 3 was examined in asynchro-
nously growing HeLa cells, as described above. These studies
demonstrated that relative to parent 2c, peptide 3 showed
a greatly improved ability to induce mitotic block, reaching a
maximum mitotic index of approximately 80% at 24 hr at a
concentration of 400 mM as compared to approximately 60%
for 2c under the same conditions and roughly 18% for 2ay (Fig-
ure 3). The potency of the S/A mutant 3(S4A) was very similar
to vehicle control, strongly supporting the PBD-dependence of
mitotic block by 3 (Figure 3). The anti-proliferative potency of 3
(IC50 = 55 mM) was also improved significantly relative to 2c
(IC50 = 85 mM; Figure 4).264, October 24, 2013 ª2013 Elsevier Ltd All rights reserved 1259
Figure 4. Dose-Dependent Inhibition for Cell Proliferation by the Indicated Peptides
Asynchronously growing HeLa cells were treated with various concentrations of the indicated compounds. The resulting cells were harvested at the 0, 12, 24, and
48 hr time points and then quantified. The relative cell numbers for the indicated time points were determined in comparison to those of the respective 0 hr time
point sample. The IC50 values of cell proliferation inhibition for indicated compounds were calculated using the data points from the 48 hr samples.R
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Peptidic pThr Esters Targeting Plk1 PBDDISCUSSION
Because Plk1 is overexpressed in a wide spectrum of human
cancers and is considered an attractive anticancer drug
target, development of specific and potent anti-Plk1 inhibitors
would be very much needed. However, the current prevailing
strategy of inhibiting the catalytic activity of the kinase has
suffered from a high level of cross-reactivity with Plk2 and
Plk3, and other structurally related kinases. Therefore, as an
alternative strategy, we have taken advantage of the 5-mer
phosphopeptide PLHSpT (1) (Yun et al., 2009) to develop
several di-anionic derivatives that specifically bind to Plk1
PBD with unusually high binding affinity (with KD values in the1260 Chemistry & Biology 20, 1255–1264, October 24, 2013 ª2013 Elow nanomolar range; Liu et al., 2011, 2012a, 2012b). Although
these initial efforts were encouraging, testing of 2ay in cell-
based assays revealed low efficacy, potentially due to ineffi-
cient membrane transit (Liu et al., 2011). Therefore, our current
findings are significant in that improved potencies relative to
the dianionic peptide 2ay were exhibited by peptides containing
mono-anionic pThr esters. Additional improvements in mem-
brane permeability and stability are likely to be required to
further enhance the potency of these inhibitors. Progress in
this direction is shown by our demonstration that conversion
of the mono-anionic 2c to its neutral prodrug 3 can potently
induce mitotic block and apoptotic cell death in cultured cancer
cells.lsevier Ltd All rights reserved
Table 3. Pre-Incubation-Dependent Plk1 PBD Binding
Entry Compound
IC50 (mM)
Withouta Withb
1 PLHSpT (1) 16 2
2 2a 0.002 0.001
3 2c 0.002 0.001
6 2c(S4A) 1.3 0.2
4 2 m 0.002 0.001
7 2 m(S4A) 0.3 0.06
5 3 0.02 0.002
8 3(S4A) 28 1
Binding curves are shown in Figure S5. See also Figure S6.
aCell lystates were incubated (1.5 hr) without peptide prior to performing
binding studies (1 hr incubations).
bCell lysates were preincubated with peptide (1.5 hr) prior to performing
binding studies (1 hr incubations).
Chemistry & Biology
Peptidic pThr Esters Targeting Plk1 PBDIn our current work, a key structural aspect of reducing phos-
phoryl anionic charge without loss of inhibitory potency involved
the use of high affinity auxiliary interactions of a tethered alkyl-
phenyl ring within a cryptic hydrophobic binding pocket (Liu
et al., 2011, 2012a, 2012b). The recent report that tethered alkyl
functionality can dramatically increase binding affinity of a phos-
phodiesterase 2 (PDE2) inhibitor by accessing a binding-induced
hydrophobic pocket (Zhu et al., 2013), may potentially indicate a
broader use of this approach to increase ligand affinity in phos-
pho-dependent interactions. However, the extensive network of
solvent-bridged interactions surrounding the phosphoryl group
within the PBD pThr-binding pocket is unique among protein-
phosphopeptide complexes in which the phospho group is
bound by positively charged residues (Elia et al., 2003a). Accord-
ingly, compensatory displacement of bound waters as a mech-
anism of enhancing the affinity of phosphoryl esters may be
more prominent in PBDs as compared to other phospho-binding
systems. Nonetheless, the strategy described herein represents
a significant advance in the development of PBD-binding inhib-
itors that may also find use in the design and development of
phosphate-containing inhibitors in other contexts.
SIGNIFICANCE
Despite their potential therapeutic applications, inhibitors of
phospho-dependent PPIs present particular challenges for
the development of cell-permeable binding antagonists
due to the critical roles traditionally played by the di-anionic
phosphoryl moiety in ligand affinity and the impediments
that these charged groups present to cell membrane transit.
The Plk1 PBD is an emerging potential anticancer target.
However, to date, high PBD-binding affinity has required
interaction of di-anionic chargewithin the pThr/pSer binding
pocket. Our current work significantly advances the field of
Plk1 PBD-binding inhibitor development by its discovery
that mono-anionic pThr-containing peptides can retain
extremely high affinity. A key aspect of our findings is that
concomitant auxiliary binding in a recently discovered
cryptic binding channel is required to achieve high binding
affinity of the mono-anionic phoshoryl species. We provide
R
ET
R
AChemistry & Biology 20, 1255–1crystallographic data that show interactions of the key
phosphoryl ester group within the pThr-binding pocket,
which indicate that binding with the key Lys538 residue
need not be ionic in nature. Additionally our observation of
the displacement of several bound waters from the pThr-
binding pocket by phosphoryl ester functionality suggests
that this may contribute to binding affinity. Our application
of prodrug protection is particularly attractive because
cleavage of only a single POM group is required to liberate
the biologically active mono-anionic phosphoryl ester. This
overcomes potential limitations of esterase-mediated
hydrolysis thatmay arisewhen bis-deprotection to a di-ionic
species is required. Our findings represent a significant
advance in the development of Plk1 PBD-binding inhibitors
that may have broader applicability to the development of
antagonists of other phospho-dependent PPIs.
EXPERIMENTAL PROCEDURES
On-Resin Synthesis of Mono-anionic pThr Esters: 2b–2n
Fmoc-protected amino acids were purchased from Novabiochem. Phospho-
threonine was used in the Fmoc-Thr(PO(OBzl)OH)-OH form and Fmoc-
His(N(p)-Ph(CH2)8-)-OH was prepared according to literature procedures
(Qian et al., 2011). Peptides were synthesized on NovaSyn TGR resin (Nova-
biochem, cat. no. 01-64-0060) or NovaSyn TG Siber resin (Novabiochem,
cat. no. 01-64-0092) using standard Fmoc-based solid-phase protocols
in N-methyl-2-pyrrolidone (NMP). 1-O-Benzotriazole-N,N,N0,N0-tetramethyl-
uronium-hexafluoro-phosphate (HBTU; 5.0 eq.), hydroxybenzotriazole
(HOBT; 5.0 eq.), and N,N-diisopropylethylamine (DIPEA; 10.0 eq.) were used
as coupling reagents. Amino terminal acetylation was achieved using 1-acety-
limidazole (10 eq.) in DMF. The resins SI-1 or SI-2 (0.1 mmol; Figure S1) were
swelled in CH2Cl2 (15 min) and then treated with triphenylphosphine (262 mg,
1.0 mmol), diethyl azidodicarboxylate (DEAD; 0.46 ml, 40% solution in
toluene, 1.0 mol) and alchohols b–n (Figure S1; 1.0 mmol) in dry CH2Cl2 at
room temperature (4 hr), then washed (CH2Cl2) and dried under vacuum
overnight. Resins were then cleaved by treatment with trifluoroacetic acid
(TFA): triispropylsilane (TIS): H2O (95: 2.5: 2.5) (5 ml, 4 hr). The resin was
removed by filtrations and the filtrate was concentrated under vacuum, the
residue was dissolved in 50% aqueous acetonitrile (CH3CN; 5 ml) and
purified by reverse-phase preparative HPLC using a Phenomenex C18 column
(21 mm 3 250 mm, cat. no: 00G-4436-P0) with a linear gradient from 20%
aqueous CH3CN (0.1% TFA) to 90% CH3CN (0.1% TFA acid) over 30 min at
a flow rate of 10.0 ml/min. Lyophilization gave the desired products 2b–2n
as white powders (Figure S1). Peptide 2awas prepared as previously reported
(Qian et al., 2011).
Synthesis of Fluorescein Isothiocyante-Labeled Peptides for Plk
Specificity Determination
The resin-bond peptide SI-3 (Figure S4) was synthesized by standard Fmoc
solid-phase peptide-protocols as outlined above, and the amino-terminus
was acylated with Fmoc-N-amido-dPEG 8-NHS ester (3.0 eq.) (Quanta
Biodesign, Cat# 10995) by reacting with HBTU (5.0 eq.), HOBt (5.0 eq.), and
DIPEA (10.0 eq.) at room temperature (4 hr). On-resin Mitsunobu phosphoryl
esterification was then performed as indicated above for the synthesis of pep-
tides 2 (Figure S1) to form the resin-bound peptides SI-4 and SI-5 (Figure S4).
Following Fmoc deprotection, the resins were treated with the fluorescein iso-
thiocyanate (FITC; open-form isomer I; 5.0 eq.) and DIPEA (10.0 eq.) in NMP
(12 hr). (Note: Performing installation of the FITC group prior to Mitsunobu
esterification yielded complex products following resin cleavage.) Finished
resins were washed sequentially with DMF, MeOH, CH2Cl2, and ether, dried
under vacuum (1 hr) and subjected to TFA-mediated cleavage as described
above for the synthesis of peptide 2 and purified by high-performance liquid
chromatography (HPLC) to provide the desired peptides 2c* and 2m* as white
powders. Analytical data are provided in Figure S4. Peptide 2a* was synthe-
sized as previously described (Liu et al., 2011).
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Synthesis of peptides 3 and 3(S4A), which represents peptides 2c and
2c(S4A) having their second phosphoryl hydroxyls derivatized as a piva-
loyloxymethyl (POM) ester, was achieved as outlined in Figure S5. Solid-
phase peptide synthesis was conducted as indicated above for the
synthesis of resin-bound peptides SI-1 and SI-2 (Figure S1) except
that Fmoc-Thr(PO(OPOM)OH)-OH (SI-6) was used in place of Fmoc-
Thr(PO(OBzl)OH)-OH to yield the resin-bound peptides SI-7 and SI-8 (Fig-
ure S5). On-resin Mitsunobu phosphoryl esterification was then performed
as indicated above for the synthesis of peptides 2 (Figure S1) to form the
resin-bound POM protected pThr monoester containing peptides. The result-
ing resins were cleaved using TFA as indicated above and purified by HPLC
to provide peptides 3 and 3(S4A) as white powders. Analytical data are
provided in Figure S5.
ELISA-Based PBD-Binding Inhibition Assay
A biotinylated p-T78 peptide was first diluted with 13 coating solution (KPL) to
the final concentration of 0.3 mM, and then 100 ml of the resulting solution was
immobilized onto a 96-well streptavidin-coated plate (Nalgene Nunc). The
wells were washed once with PBS plus 0.05% Tween20 (PBST), and incu-
bated with 200 ml of PBS plus 1% BSA (blocking buffer) for 1 hr to prevent
nonspecific binding. Mitotic 293A lysates expressing HA-EGFP-Plk1 were
prepared in TBSN buffer (60 mg total lysates in 100 ml buffer), mixed with
the indicated amount of the competitors (p-T78 peptide and its derivative com-
pounds), provided immediately onto the biotinylated peptide-coated ELISA
wells, and then incubated with constant rocking for 1 hr at 25C. Following
the incubation, ELISA plates were washed four times with PBST. To detect
bound HA-EGFP-Plk1, the plates were probed for 2 hr with 100 ml/well of
anti-HA antibody at a concentration of 0.5 mg/ml in blocking buffer and then
washed five times. The plates were further probed for 1 hr with 100 ml/well of
HRP-conjugated secondary antibody (GE Healthcare) at a 1:1,000 dilution in
blocking buffer. The plates were washed five times with PBST and incubated
with 100 ml/well of 3,30,5,50-tetramethylbenzidine (TMB) solution (Sigma) as a
substrate until a desired absorbance was reached. The reactions were
stopped by the addition of 100 ml/well of stop solution (Cell Signaling Technol-
ogy). The OD450 by using an ELISA plate reader (Molecular Devices). Data are
shown in Table 1 and Figure S2.
PBD Fluorescence Polarization Binding Assays for Plk1, Plk2,
and Plk3
5-carboxyfluorescein-labeled peptides 2a*, 2c*, and 2 m* were incubated, at
a final concentration of 2 nM, with various concentrations of bacterially ex-
pressed purified PBDs of Plk1, Plk2, and Plk3 in a binding buffer containing
10 mM Tris (pH 8.0), 1 mM EDTA, 50 mM NaCl, and 0.01% Nonidet P-40.
Fluorescence polarization was analyzed 10 min after mixing of all compo-
nents in a 384-well format using a Molecular Devices SpectraMax Paradigm
Multi-Mode Microplate Detection Platform. All experiments were performed
in triplicate. Obtained data were plotted using GraphPad Prism software
version 6. KD values are provided in Table 2 and binding curves are shown
in Figure S4.
Stability of Prodrug Protected Peptide 3 to Enzymatic Deprotection
Pig Liver Esterase Hydrolysis of Peptide 3
Following literature procedures (Srivastva and Farquhar, 1984), 0.05 M potas-
sium phosphate buffer (pH 7.4) was placed in a centrifuge tube and a solution
of peptide 3 in MeOH was added to the buffer to achieve a concentration of
200 mM of 3 with MeOH being less than 1%. Pig liver esterase (57.6 units)
was added to a 1 ml aliquot of the above solution and the reaction mixture
was incubated at 37C with gentle agitation. At various time points, aliquots
of the reactionmixture (50 ml) were transferred to an Eppendorf tube containing
MeCN (50 ml). Following filtration, the hydrolysis product was monitored
with liquid chromatography-mass spectrometry (LC-MS). Data are shown in
Figure S6.
Hydrolysis of Peptide 3 in Cell Culture Media
Fetal bovine serum (FBS; cat. SH30396, Thermo Scientific; 50ml); Antimycotic
(cat. 15240-112, Life Technologies; 5 ml), Glutamax (cat. 35050-079, Life
Techonologies; 5 ml); and HEPES buffer (cat. 15630-130, Life Technologies;
12.5 ml) was added to an aliquot of culture medium consisting of Dulbecco’s
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11960, Life Technologies]; Dulbecco and Freeman, 1959); a solution of peptide
3 in MeOH to achieve a concentration of 1 mM of 3 with MeOH being less than
1%. The reaction mixture was then incubated at 37C with gentle shaking. At
various time points, aliquots of the reaction mixture (50 ml) were transferred to
an Eppendorf tube containing MeCN (50 ml). Following filtration, the hydrolysis
product was monitored with LC-MS. Data are shown in Figure S6.
Hydrolysis of Peptide 3 by Total Cell Lysates
Mitotic 293A cells expressing HA-EGFP-Plk1 were lysed at 4C using lysis
buffer consisting of 50 mM Tris-HCl, pH 8.0; 120 mM NaCl; 5% nonyl phenox-
ypolyethoxylethanol (Tergitol-type NP-40); 5 mM ethylene glycol tetraacetic
acid (EGTA); 1.5 mM ethylenediaminetetraacetic acid (EDTA); 4-nitrophenyl
phosphate di(tris) salt (PNPP; cat. N3254, Aldrich; (0.1 g/10 ml) and protease
inhibitor (cOmplete EDTA-free; cat. 11873580001, Roche). The lysate was
centrifuged (13,000 rpm, 15 min, 4C) and the resulting cell lysate supernatant
was placed in 96-well plates. A solution of peptide 3 in DMSOwas added to the
wells so that the concentration of the peptide was 1 mMwith DMSO being at a
concentration of less than 1% and a total volume of 125 ml. The reaction mix-
tures were incubated at 37C with gentle shaking. At different time points,
MeCN (125 ml) was added to eachwell to quench the reactions. Following filtra-
tion, the hydrolysis products were monitored with LC-MS. Data are shown in
Figure S6.
Cell Culture, Analysis of Cellular Proliferation, Aberrant Mitotic
Population, and Indirect Immunofluorescence Microscopy
HeLa cervical carcinomaCCL2 and 293A cells were cultured as recommended
by the American Type Culture Collection. To prepare mitotic 293A cells ex-
pressing HA-EGFP-Plk1, cells were infected with adenovirus expressing HA-
EGFP-Plk1 and arrested with 200 ng/ml of nocodazole for 16 hr. To analyze
the effect of the indicated compounds in cultured cells, logarithmically growing
HeLa cells were treated with various concentrations of the indicated com-
pounds for 12, 24, and 48 hr. Images of HeLa cells were acquired using a Zeiss
Axiovert 100 Mmicroscope (Carl Zeiss MicroImaging). Effects of treatment on
mitotic block and cellular proliferation are shown in Figures 3 and 4.
X-Ray Crystallography
Protein Purification and Crystallization
Plk1 PBDprotein (residues 371–603) was purified as previously described (Yun
et al., 2009). Crystals were grown using the hanging drop vapor diffusion
method. PBDprotein at 12mg/ml in 10mMTris pH8, 0.5MNaCl, 10mMdithio-
threitol, 1% (v/v) DMSO, and 1mMof peptide 2mwasmixedwith an equal vol-
ume of reservoir solution consisting of 13% (w/v) PEG 3350, 0.1 M HEPES
pH 7.5, and 100 mM NaCl. Crystals began appearing overnight and reached
maximum size over several days. Crystals grew in clusters that were manually
broken up to obtain sufficiently single crystals suitable for data collection.
Data Collection and Structure Determination and Refinement
Crystals were cryoprotected in 26% (w/v) PEG 3350, 0.1 M HEPES pH 7.5,
150 mM NaCl, 6% (v/v) glycerol, 1 mM 2 m, 1% (v/v) DMSO, and 10 mM
DTT, and data were collected at 100 K on a Rigaku Raxis-IV image plate de-
tector with a Rigaku RU-300 home X-ray source. The data were processed
with the HKL (Minor et al., 2006) and CCP4 (CCP4, 1994) software suites.
The structure was solved by molecular replacement using AMoRe (Navaza,
2001) using chain A of structure 3FVH (RCSB accession code; Yun et al.,
2009) as a search model, and refined using PHENIX (Adams et al., 2010)
with manual fitting in XtalView (McRee, 1999). Refinement statistics and a
sigmaA weighted 2Fo-Fc electron density map are provided in Figure S3.
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